Consolidated revenue from operations of the corporate stood at Rs 1,153.9 crore for the quarter into account. It was Rs 884.2 crore for a similar interval a 12 months in the past, it added.
“Regardless of the challenges from the second wave of COVID within the nation, by way of manpower availability and provide chain bottlenecks, Gland Pharma has managed to ship sturdy quarterly outcomes,” Gland Pharma Managing Director and Chief Government Officer Srinivas Sadu mentioned.
The corporate’s key markets, the US, Canada, Europe, and Australia registered a development of 16 p.c and accounted for 61 p.c of income throughout the first quarter of the monetary 12 months 2021-22, Gland Pharma mentioned.
India accounted for 20 p.c of the primary quarter of the monetary 12 months 2021-22 income and witnessed a 77 p.c year-on-year development for the quarter. To assist the home market requirement throughout the second wave of COVID-19, the corporate ramped up the availability of important medicine like remdesivir and enoxaparin, it added.
The remainder of the World’s markets have seen a sturdy development of 51 p.c consistent with the corporate’s elevated concentrate on geographic growth, Gland Pharma mentioned.
The corporate additionally mentioned that its board has accepted the appointment of Udo Johannes Vetter as an Unbiased Director, with impact from July 21, 2021, for a tenure of 5 years.